E-Qure Corp.
EQUR
Other OTC0.00
USD
-0.04
- -
CIK
0001563536
ISIN
US26885P1093
CUSIP
26885P109
Return %
Stock
S&P500
1Y
-99.05
26.53
3Y
-99.75
76.60
5Y
-99.78
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Ohad Goren
- Full Time Employees
- 1
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 20 West 64th Street New York City NY United States of America 10023
- IPO Date
- Oct 31, 1994
- CIK
- 0001563536
- Website
- e-qure.com
- Similar Companies
- Business
- E-Qure Corp. operates as a medical device company specializing in the development and commercialization of bioelectrical signal therapy (BST) devices. Its core product, the BST device, utilizes patented and proprietary electrical stimulation technologies aimed at treating hard-to-heal wounds and ulcers, including pressure ulcers, diabetic foot ulcers, and venous leg ulcers, facilitating wound closure and healing. The company’s BST therapy offers a non-invasive, painless treatment intended for both home and clinical care settings and complies with international regulatory standards, with approvals in Europe (CE), Australia, Canada, and Israel. Founded in 1988 and headquartered in New York, New York, E-Qure's primary operations include product design, production, regulation, and distribution primarily targeting chronic wound care markets across multiple geographies. In recent developments, E-Qure has focused on advancing the commercialization of its BST device technology, maintaining its strategic emphasis on treating chronic wounds via electrical stimulation therapy which is recognized as an effective approach by leading medical institutions. The company has pursued operational improvements and market penetration efforts over the last one to two years, but has not publicly disclosed major acquisitions, partnerships, or new product lines within that time frame. Its medical device offering remains central to its market presence, addressing substantial healthcare challenges related to chronic wounds, with ongoing compliance and distribution activities supporting broader adoption. E-Qure continues to target healthcare providers and patients in regions including Europe, North America, and Australia through its regulatory certifications and market outreach. The company’s small-scale workforce and focused product portfolio underscore its niche positioning in the medical device industry specializing in advanced wound care technology.
Head-To-Head Review: Waters (NYSE:WAT) and ADB International Group (OTCMKTS:EQUR)
Contrasting Delcath Systems (NASDAQ:DCTH) & ADB International Group (OTCMKTS:EQUR)
Analyzing ADB International Group (OTCMKTS:EQUR) & Neuronetics (NASDAQ:STIM)